On the other hand, although the MEK/ERK MAPK pathway is known for its role in cell proliferation, there is little evidence that MAPK activity is increased in prostate cancer and interactions between Rac1/PAK1 and MEK/ERK is likely to be cell type-dependent [65]. Here, RAC1 is linked to prostate cancer.